Literature DB >> 20872196

Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors.

Lin Xia1, Ming-Ming Zhang, Lin Ji, Xin Li, Xiao-Ting Wu.   

Abstract

PURPOSE: To evaluate the effectiveness of resecting liver metastases of gastrointestinal stromal tumors (GISTs), when performed in conjunction with imatinib treatment.
METHODS: Forty-one patients with pathologically diagnosed GIST and liver metastases were randomly assigned to an operation group (neoadjuvant therapy + resection + adjuvant therapy with imatinib) or a nonoperation group (imatinib alone). Patients were monitored for up to 36 months, and survival was analyzed.
RESULTS: We monitored 39 patients throughout the 36-month follow-up period, recording 1- and 3-year survival rates of 100% and 89.5% in the operation group and 85% and 60% in the nonoperation group, respectively. There was a significant difference in overall survival between the operation and nonoperation groups (P = 0.03). Furthermore, resection improved the survival of patients who responded poorly to 6 months of preoperative imatinib treatment, compared with that of their counterparts in the nonoperation group (P = 0.04).
CONCLUSION: These findings suggest that surgical intervention in combination with imatinib treatment is more effective than imatinib alone against GIST liver metastases, with minimal complications and side effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20872196     DOI: 10.1007/s00595-009-4171-x

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  19 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

Review 3.  Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.

Authors:  Florian Haller; Sven Detken; Hans-Jürgen Schulten; Nicole Happel; Bastian Gunawan; Jens Kuhlgatz; László Füzesi
Journal:  Ann Surg Oncol       Date:  2006-12-02       Impact factor: 5.344

4.  Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas.

Authors:  Souya Nunobe; Tsuyoshi Sano; Kazuaki Shimada; Yoshihiro Sakamoto; Tomoo Kosuge
Journal:  Jpn J Clin Oncol       Date:  2005-05-31       Impact factor: 3.019

5.  Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.

Authors:  Robert H I Andtbacka; Chaan S Ng; Courtney L Scaife; Janice N Cormier; Kelly K Hunt; Peter W T Pisters; Raphael E Pollock; Robert S Benjamin; Michael A Burgess; Lei L Chen; Jonathan Trent; Shreyaskumar R Patel; Kevin Raymond; Barry W Feig
Journal:  Ann Surg Oncol       Date:  2007-01       Impact factor: 5.344

6.  The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.

Authors:  Isis Gayed; Thuan Vu; Revathy Iyer; Marcella Johnson; Homer Macapinlac; Nancy Swanston; Donald Podoloff
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

7.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

8.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Authors:  Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

9.  Neoadjuvant imatinib in a gastrointestinal stromal tumor of the rectum: report of a case.

Authors:  Yuma Ebihara; Shunichi Okushiba; You Kawarada; Shuji Kitashiro; Hiroyuki Katoh; Satoshi Kondo
Journal:  Surg Today       Date:  2008-02-01       Impact factor: 2.549

10.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

View more
  25 in total

1.  Safe laparoscopic resection of a gastric gastrointestinal stromal tumor close to the esophagogastric junction.

Authors:  Yasuo Sakamoto; Yoshihisa Sakaguchi; Hisafumi Akimoto; Yoshiki Chinen; Miyako Kojo; Masahiko Sugiyama; Kazutoyo Morita; Hiroshi Saeki; Kazuhito Minami; Yuji Soejima; Yasushi Toh; Takeshi Okamura
Journal:  Surg Today       Date:  2012-01-24       Impact factor: 2.549

2.  Survival After Resection of Gastrointestinal Stromal Tumor and Sarcoma Liver Metastases in 146 Patients.

Authors:  Kristoffer W Brudvik; Sameer H Patel; Christina L Roland; Claudius Conrad; Keila E Torres; Kelly K Hunt; Janice N Cormier; Barry W Feig; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  J Gastrointest Surg       Date:  2015-05-22       Impact factor: 3.452

Review 3.  The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review.

Authors:  Timothy L Fitzgerald; Jason Brinkley; Shannon Banks; Nasreen Vohra; Zachary P Englert; Emmanuel E Zervos
Journal:  Langenbecks Arch Surg       Date:  2014-08-23       Impact factor: 3.445

4.  Effective Downsizing of a Gastroesophageal GIST Using Neoadjuvant Imatinib Mesylate: a Case Report.

Authors:  Syed Asif; Nikhil Gupta; Gurudutt Gupta; Anurag Mehta; Shivendra Singh
Journal:  J Gastrointest Cancer       Date:  2017-06

Review 5.  Management of liver metastases from gastrointestinal stromal tumors: where do we stand?

Authors:  Nikolaos Machairas; Anastasia Prodromidou; Ernesto Molmenti; Ioannis D Kostakis; Georgios C Sotiropoulos
Journal:  J Gastrointest Oncol       Date:  2017-12

6.  Laparoscopic resection of a gastrointestinal stromal tumor of the rectum after treatment with imatinib mesylate: report of a case.

Authors:  Takatoshi Nakamura; Hiroyuki Mitomi; Wataru Onozato; Takeo Sato; Atsushi Ikeda; Masanori Naito; Naoto Ogura; Hiroki Kamata; Akira Ooki; Masahiko Watanabe
Journal:  Surg Today       Date:  2012-11       Impact factor: 2.549

Review 7.  Surgery for metastatic gastrointestinal stromal tumor: to whom and how to?

Authors:  Hirotoshi Kikuchi; Yoshihiro Hiramatsu; Kinji Kamiya; Yoshifumi Morita; Takanori Sakaguchi; Hiroyuki Konno; Hiroya Takeuchi
Journal:  Transl Gastroenterol Hepatol       Date:  2018-03-05

Review 8.  Metastasectomy for gastrointestinal stromal tumors.

Authors:  Zubin M Bamboat; Ronald P DeMatteo
Journal:  J Surg Oncol       Date:  2013-10-24       Impact factor: 3.454

9.  Outcomes After Surgical Resection Differ by Primary Tumor Location for Metastatic Gastrointestinal Stromal Tumors (GISTs): a Propensity Score Matching Population Study.

Authors:  Apostolos Gaitanidis; Michail Alevizakos; Alexandra Tsaroucha; Michail Pitiakoudis
Journal:  J Gastrointest Cancer       Date:  2019-12

10.  A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis.

Authors:  Sebastian G de la Fuente; Jeremiah L Deneve; Colin M Parsons; Jonathan S Zager; Anthony P Conley; Ricardo J Gonzalez
Journal:  HPB (Oxford)       Date:  2012-12-27       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.